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Running head 
Universal screening for LS among Chinese CRC patients  
 
Key words：Colorectal cancer; Lynch Syndrome; universal screening; ethnic diversity 
 
Abbreviations 
LS, Lynch syndrome; MMR, mismatch repair; CRC, colorectal cancer; dMMR, MMR 
protein deficiency; IHC, immunohistochemical; PCR, polymerase chain reaction; 
CNV, copy number variations; InSiGHT, International Society of Gastrointestinal 
Hereditary Tumors; LOVD, Leiden Open Variation Database; VUS, variants of 
uncertain significance 
 
Novelty & Impact Statements 
The current study demonstrated that there are unique molecular features in a large 
consecutive Chinese colorectal cancer cohort undergoing universal screening for 
Lynch Syndrome, characterized by high prevalence and infrequent BRAF
V600E
 
mutation. These results verified the ethnic diversity among lynch syndrome. Patients 
older than 65 years who do not meet the revised Bethesda guidelines have a low risk 
of lynch syndrome, suggesting germline sequencing might not be necessary in this 
population. 
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ABSTRACT 
The prevalence of Lynch syndrome (LS) varies significantly in different populations, 
suggesting that ethnic features might play an important role. We enrolled 3330 
consecutive Chinese patients who had surgical resection for newly diagnosed 
colorectal cancer. Universal screening for LS was implemented, including 
immunohistochemistry for mismatch repair (MMR) proteins, BRAF
V600E
 mutation test 
and germline sequencing. Among the 3250 eligible patients, MMR protein deficiency 
(dMMR) was detected in 330 (10.2%) patients. Ninety-three patients (2.9%) were 
diagnosed with LS. Nine (9.7%) patients with LS fulfilled Amsterdam criteria II and 
76 (81.7%) met the revised Bethesda guidelines. Only 15 (9.7%) patients with 
absence of MLH1 on IHC had BRAF
V600E
 mutation. One third (33/99) of the MMR 
gene mutations have not been reported previously. The age of onset indicates risk of 
LS in patients with dMMR tumors. For patients older than 65 years, only 2 patients 
(5.7%) fulfilling revised Bethesda guidelines were diagnosed with LS. Selective 
sequencing of all cases with dMMR diagnosed at or below age 65 years and only of 
those dMMR cases older than 65 years who fulfill revised Bethesda guidelines results 
in 8.2% fewer cases requiring germline testing without missing any LS diagnoses. 
While the prevalence of LS in Chinese patients is similar to that of Western 
populations, the spectrum of constitutional mutations and frequency of BRAF
V600E
 
mutation is different. Patients older than 65 years who do not meet the revised 
Bethesda guidelines have a low risk of LS, suggesting germline sequencing might not 
be necessary in this population. 
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Introduction 
Lynch syndrome (LS), is the most common hereditary colorectal cancer (CRC) 
syndrome, accounting for 2%-4% of all CRC cases.
1-4
 LS is caused by germline 
mutations in one of four mismatch repair (MMR) genes (MLH1, MSH2, MSH6 and 
PMS2)
5
, or deletions in the 5’ area of EPCAM which result in hypermethylation of the 
MSH2 promoter and subsequent MSH2 silencing.
6, 7
 Patients with LS are susceptible 
to various cancers and often at a young age.
8-11
 Both the US National Comprehensive 
Cancer Network Clinical Practice Guidelines in Oncology for Genetic/Familial 
High-Risk Assessment (Colorectal) and the National Institute for Health and Care 
Excellence (NICE) in the UK now recommend universal screening of all CRC to 
improve the identification of individuals with LS.
12, 13
 The prevalence of LS varies 
significantly in different populations, suggesting that ethnic diversity might play an 
important role in the disease. To our knowledge, screening for LS has been mainly 
performed in western populations and data regarding Chinese patients is scarce. 
Because of China’s large population, delineation of the prevalence and genotype of 
LS in Chinese patients would help to understand the ethnic diversity of LS. 
 
Since the universal screening strategy has been gradually adopted worldwide, it is 
interesting to explore the prevalence of LS in patients with MMR protein deficiency 
(dMMR) in different age of onset. In this way, we could identify the patients with 
high risk of LS for germline sequencing and optimize the screening strategy. 
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Herein, we conducted universal screening for LS in a consecutive large cohort with 
newly diagnosed CRC, using immunohistochemical (IHC) staining for MMR proteins, 
followed by BRAF
V600E 
testing in cases with absence of MLH1, and then multigene 
panel testing on germline DNA in all cases with dMMR and no BRAF
V600E
 mutation. 
We investigated the prevalence of dMMR and LS in these unselected CRC patients 
and further evaluated the associations between age of onset and prevalence of LS in 
patients with dMMR tumors. Finally, the efficiency of a selective strategy consisting 
of universal tumor MMR testing and specific clinical criteria was tested.  
 
Materials and Methods 
Patients and Screening strategy 
Between November 2011 and December 2015, 3330 consecutive patients who had 
surgical resection for newly diagnosed colorectal adenocarcinoma at the Sun Yat-sen 
University Cancer Center, China were enrolled in this study. Eighty patients with a 
clinical diagnosis of polyposis or with insufficient tumor tissue for IHC were 
excluded. The protocol was approved by the clinical research ethics committee of the 
Cancer Center. All patients provided written informed consent to participate in the 
study. All data in our study have been recorded at Sun Yat-sen University Cancer 
Center for future reference (number RDDA2018000384). 
 
The screening strategy is detailed in Figure 1. In brief, IHC for four MMR proteins 
was performed universally to identify patients with dMMR as evidenced by the 
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absence of one or more of the MMR proteins. If the MLH1 protein was absent, 
BRAF
V600E
 mutation testing was performed in the tumor to exclude cases with 
suspected MLH1 gene promoter methylation. Patients with dMMR and no BRAF
V600E
 
mutation were referred for genetic counseling and identified as candidates for 
germline sequencing. 
 
IHC and BRAF
V600E
 mutation testing 
All specimens were prepared as 4μm FFPE sections. The sections were tested by a 
validation program in the Leica-bond system (Leica Biosystems Nussloch GmbH, 
Germany). Primary monoclonal antibodies against MLH1 (cloneES05; ZSGB-BIO, 
Beijing, China), MSH2 (clone RED2; ZSGB-BIO, Beijing, China), MSH6 (clone 
EP49; ZSGB-BIO, Beijing, China), and PMS2 (cloneEP51; ZSGB-BIO, Beijing, 
China) were applied to the sections. Protein expression was assessed by two 
independent pathologists (CMY, LYH). Protein deficiency was defined as absence of 
nuclear staining within tumor cells and positive nuclear staining in normal tissues as 
internal control. Preserved expression was defined as nuclear staining in tumor cells 
with consistent labeling in control cells. 
 
The BRAF
V600E
 mutation within exon 15 was detected using fluorescent real-time 
polymerase chain reaction (PCR). Genomic DNA was amplified in a 24μL PCR 
reaction with 7500 real-time fluorescence quantitative PCR system (Applied 
Biosystems, Foster City, CA). Mutations were confirmed with independent duplicate 
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analyses. 
 
Germline DNA sequencing and Variant classification 
DNA was extracted from peripheral blood samples by QIAamp DNA Blood Mini Kit 
(QIAGEN, Hilden, Germany) according to the manufacturer’s standard protocol. 
NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA) was used to assess 
the DNA quality and concentration. Qualified DNA samples were used to do the 
library construction. The insert size and quantity of the library were assessed by 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, MA, USA) instrument and 
enrichment of the target region was assayed by qPCR. After quality control, the 
library was sequenced by a multigene panel using the HiSeq platform, in which the 
target regions of MLH1, MSH2, MSH6, PMS2 and EPCAM were covered. 
 
After filtering the low quality reads, clean sequencing data were aligned to reference 
(UCSC, hg19) using BWA0.6.2 (Burrow-wheeler Aligner), marked for duplication by 
Picard (V1.98) and re-aligned by GATK (v3.5, Broad Institute, Cambridge, MA, 
USA). After that, the final mapping file (BAM format) was used to detect the 
SNP/InDel by GATK software. In-house developed software was used to detect gene 
exonic deletion/duplication mutation. SNP/InDel mutations with less than 25% 
mutational frequency were filtered. Mutations were annotated based on RefSeq GTF 
file. The SNP frequency was annotated by Dbsnp141, ExAC, 1000 genomes project 
and so on. The pathogenicity of mutations was classified according to American 
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College of Medical Genetics and Genomics (ACMG) recommendations.
14
 All the 
pathogenic and likely pathogenic SNP/InDel mutations were confirmed by Sanger 
sequencing. All the copy number variations (CNV) were validated by qPCR method. 
 
Domain region in the MMR genes was defined by Pfam database. We took the known 
pathogenic missense mutations from our in-house database as positive control and the 
in-house benign missense database and mutations with >0.01 allele frequency in 
human published databases served as a negative control. If one domain region only 
contains pathogenic mutation, it was defined as a highly conserved functional domain. 
Those mutations located in highly conserved regions were considered as moderate 
evidence for pathogenic nature. Any missense mutations of uncertain significance 
were re-evaluated for their location, in silico prediction results, phenotype, family 
history, and also checked against the International Society of Gastrointestinal 
Hereditary Tumors (InSiGHT) reference Leiden Open Variation Database (LOVD) at 
http://www.insight-database.org/genes in order to further assess pathogenicity. 
 
Statistical Analysis 
Demographic data were summarized as mean (± standard deviation) or frequency (%). 
Sensitivity, Specificity, positive predictive value, negative predictive value and 
diagnostic yield of screening strategies were calculated. SPSS statistical software, 
version 17(Chicago, USA: SPSS Inc.) were used to perform the analyses. 
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Results 
Prescreening for LS 
A total of 3250 patients were eligible for analysis. Men accounted for 59.8% (n = 
1942) of patients. The mean age at CRC diagnosis was 57.3 years (range, 15 to 91 
years). Abnormal IHC results were detected in 330 (10.2%) CRC tumors, including: 
158 patients (47.9%) with MLH1 loss alone or with loss of PMS2, 98 patients (29.7%) 
with absent MSH2 with or without MSH6 loss, 26 patients (7.9%) with only MSH6 
absent, 26 patients (7.9%) with only PMS2 absent, and 22 patients (6.7%) with other 
combinations (e.g. loss of 3 MMR proteins or unpaired loss). Demographic and 
clinical characteristics for the 330 patients with dMMR tumors are listed in Table 1. 
 
In 154 patients whose tumors had loss of MLH1, BRAF
V600E
 mutation testing was 
performed. Only 15 (9.7%) patients carried BRAF
V600E
 mutation which is consistent 
with a sporadic origin. Thus, the remaining 315 patients with abnormal IHC and no 
BRAF
V600E
 mutation were referred for genetic counseling. Of these, 256 (81.3%) 
agreed to undergo germline sequencing, while the other 59 patients refused further 
testing. 
 
Outcomes of Germline sequencing  
Among the 256 patients with dMMR tumors who underwent germline genetic testing, 
99 pathogenic or likely pathogenic mutations were discovered in 93 patients (eTable 1 
in the Supplement). Therefore, the prevalence of Lynch syndrome is 2.9% (93/3191) 
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in our cohort. Germline mutations in MLH1, MSH2, MSH6, PMS2, and EPCAM 
accounted for 42.4%, 36.4%, 15.2%, 5.1%, and 1.0% of all mutations, respectively. 
One third (33/99) of the mutations have not been reported previously. The c.793C>T 
missense mutation in MLH1 (7 patients) and c.1452_1455 deletion mutation in MSH2 
(6 patients) were the two most common mutations. Overall, we found 35 frameshift 
mutations, 25 nonsense mutations, 14 missense mutations, 14 CNVs, 10 splice site 
mutations and 1 in-frameshift mutation. Frameshift mutations were the most common 
type found in MLH1, MSH2 and MSH6, while pathogenic missense mutations were 
common in MLH1 (eFigure in the Supplement). 
 
There were 70 variants of uncertain significance (VUS) in MMR genes that were 
detected in 57 patients. Missense mutations were the most common type and 
accounted for 64.3% of the VUS. Twenty-seven (60%) of the missense mutations 
were consistent with IHC results, showing loss of the protein product of the mutant 
gene (eTable 2 in the Supplement). Four variants fulfilled criteria for upgrading to 
likely pathogenic. Given that the conserved functional domain without benign 
variation was established based on an in-house database, we classified these 4 patients 
as highly suspicious for having LS and therefore, close clinical follow up was 
recommended. 
 
Strategies for Screening 
Clinical strategies for LS screening were also evaluated (Table 2). Only 9 (9.7%) 
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patients with LS fulfilled Amsterdam criteria II. In addition, using the revised 
Bethesda guidelines as a prescreening method would have left 17 (18.3%) cases 
undiagnosed. Although the universal tumor screening strategy provides the greatest 
sensitivity, its positive predictive value was relatively low at 36.3%.We also evaluated 
the relationship between age of onset and prevalence of LS in patients with dMMR 
tumors: 15 of the 41 patients (36.6%) ≤40 years, 39 of 71 patients (54.9%) aged 
41–50 years, 28 of 80 patients (35.0%) aged 51–60 years, 9 of 29 patients (31%) 
aged 61–65 years, 1 of 15 patients (6.7%) aged 66–70 years, and 1 of 20 patients 
(5.0%) aged 71 years or older (Figure 2). Considering the indispensable role of tumor 
MMR status in clinical practice and the low frequency of LS in patients older than 65 
years in our cohort, a selective strategy consisting of universal tumor MMR testing 
and specific clinical criteria was tested. When germline sequencing was only 
performed in patients with dMMR tumors who were diagnosed at 65 years or younger, 
and in older patients fulfilling at least 1 criterion of the revised Bethesda guidelines, 
8.2% fewer cases would be candidates for germline sequencing with none of the LS 
patients being missed and positive predictive value modestly improved.(Table 2)  
 
Discussion 
Previous studies have shown that universal screening of all CRC cases for LS by 
analysis of microsatellite instability or IHC for MMR proteins is the most sensitive
15
 
and probably most cost-effective strategy.
16-18
 However, its application in Chinese 
population has not been well investigated, especially in a large unselected CRC series. 
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Furthermore, there were 376,300 new diagnoses of CRC in 2015 in China
19
, nearly 
one fourth of the new cases worldwide. Although our patients were mainly from 
southern China, the results still could be a great supplementary to the ethnic diversity 
of LS and fundamental data for direct implications on clinical practice. 
 
In our study, 330 (10.2%) patients were found to have tumors with dMMR and 93 
(2.9%) were diagnosed as LS. Considering that 59 (18.7%) patients with dMMR and 
no BRAF
V600E
 mutation did not receive germline sequencing, and the possibility of 
undiagnosed LS cases with constitutional MLH1 promoter methylation
20
, the 
incidence of LS is expected to be higher than 2.9% in our population. This result was 
similar to that found in Finnish and American studies 
3, 21
, and much higher than 
reported in Mediterranean or Japanese populations where the prevalence was no more 
than 1%.
22, 23
 However, the overall incidence of dMMR CRCs found in Chinese 
patients was relatively low compared with western populations. In a population-based 
study from the Ohio metropolitan area of the United States, the incidence of dMMR 
was as high as 14%-16%.
3, 24
 These differences might be explained by the variation in 
epigenetic background among populations. It is well known that sporadic CRCs 
exhibit dMMR because of somatic inactivation of the MLH1 gene by promoter 
methylation in tumours arising along the sessile serrated pathway.
25
 In western 
population, the proportion of MLH1 absence was 70%-80% of all dMMR tumors,
22, 26
 
while it accounted for only 47.9% in our Chinese cohort. Importantly, the prevalence 
of BRAF
V600E
 mutation is much higher in CRC tumors with absence of MLH1 in 
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western countries than we found in our study population (9.9%). This is probably a 
function of the younger age of CRC diagnosis in this Chinese cohort, as somatic 
MLH1 methylation is much more common in older patients.
27
 
 
BRAF
V600E
 mutation analysis has been reported to be a valid tool to exclude LS 
because this mutation is generally absent in patients with LS and is associated with 
promoter hypermethylation of MLH1 gene in sporadic CRCs.
28
 It is recommended to 
test for the BRAF
V600E
 mutation in colorectal tumors with absence of MLH1 protein 
expression before proceeding to germline sequencing.
29
 In a population-based 
screening program for LS in Australia, 154 (75%) BRAF
V600E
 mutations were detected 
in 205 patients with lack of MLH1 protein expression.
26
 Recent studies have revealed 
that BRAF
V600E
 mutation analysis has a low negative predictive value for MLH1 
promoter methylation, especially in patients aged more than 70 years.
30
 Using BRAF 
genotyping alone as a prescreening test would increase referral rates for genetic 
testing over 2-fold compared with MLH1 methylation testing. Given the low 
incidence of BRAF
V600E
 mutation in our cohort, the test seems less efficient in 
reducing the number of patients who require germline MMR gene sequencing. Based 
upon our study results, we therefore suggest that Chinese patients with absence of 
MLH1 on IHC should go directly to germline testing rather than using BRAF
V600E 
testing for prescreening.  
 
Another strength of this study lies in the fact that we evaluated the relationship 
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between the age of onset and prevalence of LS in patients with dMMR tumors. Given 
that determination of tumor MMR status has advantages in assessing prognosis and 
directing adjuvant chemotherapy or immunotherapy as well 
31-33
, MMR or MSI 
testing is suggested in all patients with CRC nowadays.
34, 35
 Although universal tumor 
screening provides the highest sensitivity, the low positive predictive value limited its 
application in large population. We had to balance both sensitivity and positive rate, 
so that the screening strategy could be more cost-effective. According to our cohort, 
most patients with LS developed CRC in their 40s or 50s, so the prevalence of LS is 
very low (2/35, 5.7%) in CRC patients older than 65 years even with dMMR tumors. 
In this case, universal sequencing for patients with dMMR tumor might not be 
necessary, and selective sequencing of cases with dMMR and older than 65 years 
fulfilling the revised Bethesda guidelines result in 8.2% fewer cases requiring 
germline testing without missing any LS diagnoses. Since germline tests are time 
consuming and costly, the selective strategy is effective and could be an alternative 
approach for LS screening. 
 
Interestingly, two common mutations were detected in our cohort. The c.793C>T 
missense mutation accounted for 16.7% (7/42) of all pathogenic MLH1 mutation 
cases and the c.1452_1455 deletion responsible for 16.7% (6/36) of MSH2 mutation 
cases identified. Both of these mutations have been reported previously. The former 
was detected in Taiwanese LS families
36
 while the latter was found in Hong Kong 
Chinese.
37
 Since there were major emigrations in China during the last several 
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centuries, these two mutations are deemed as founder mutations inthe southern 
Chinese population. Considering that we still have several novel mutations identified 
in at least two ostensibly unrelated patients, the possibility of additional founder 
mutations existsand further study is required. 
 
Naturally, this study has limitations. First, direct assay for MLH1 promoter 
methylation was not performed, such that the incidence of epigenetic gene 
inactivation as a cause of dMMR and LS in Chinese CRC patients was unknown. 
However, the proportion of LS patients with constitutional MLH1 promoter 
methylation in other populations is only approximately 1%.
20
 So this is unlikely to be 
a large effect in our results. Furthermore, we could not address whether direct 
methylation testing is a feasible approach for enriching suspected patients for further 
sequencing than BRAF testing. The selective strategy derived from our cohort awaits 
confirmation in another cohort of patients with CRC. Additional studies will be 
indispensable to determine its cost-effectiveness. Lastly, further studies of the MMR 
genes with variants of uncertain significance, such as segregation of mutations, 
functional assays, and somatic sequencing, are important to clarify the pathogenicity 
of these mutations and guide future surveillance for these families, which will be 
facilitated by the InSiGHT MMR LOVD and Variant Interpretation Committee, now 
recognized as the ClinVar Expert Panel for MMR genes.
38
 
 
To our knowledge, this is one of the most comprehensive studies for LS in CRC 
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patients. Although the incidence of LS is similar to that of western population, the 
spectrum of mutations and frequency of sporadic dMMR indicated by MLH1 loss and 
concurrent BRAF
V600E
 mutation is quite different, supporting that LS do has ethnic 
diversity. The age of onset indicates risk of LS in CRC patients with dMMR tumors. 
Selective germline sequencing in patients with dMMR tumors diagnosed at age 65 
years or younger, and in older patients fulfilling the revised Bethesda guidelines is 
optimal and could be an alternative approach to universal tumor screening for LS. 
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Figure Legends 
Figure1 Flow diagram of the screening strategy and main results of the study  
CRC, colorectal cancer; IHC, immunohistochemistry; MMR, mismatch repair; 
dMMR, mismatch repair protein deficiency; pMMR, mismatch repairprotein 
proficiency 
 
 
Figure 2 Correlation between age of onset and prevalence of Lynch syndrome in 
patients with MMR protein deficiency  
The prevalence of Lynch syndrome (LS) is closely related to age of onset in patients 
with MMR protein deficiency. The risk of LS is very low (2/35, 5.7%) for patients 
older than 65 years even with MMR protein deficiency. 
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Tables 
Table1. Demographic and Clinical Characteristics for the 330 patients with 
MMR protein deficiency 
 
Table2. Performance of different Strategies for the Identification of Patients with 
Lynch Syndrome  
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Tables 
Table1.Demographic and Clinical Characteristics for the 330 patients with MMRprotein 
deficiency 
 
dMLH1 
Alone or With 
Partner 
(n=158) 
dMSH2 
Alone or With 
Partner 
(n=98) 
Isolate 
dMSH6 
(n=26) 
Isolate 
dPMS2  
(n=26)  
Othera 
(n=22) 
All 
(n=330) 
Age, years 
      
Mean±SD 53.2±14 51.1±11 55.5±12 55.8±10 53.4±13 53.0±13 
Sex, No. (%)      
 
Male 88 (56) 68 (70) 23 (88) 16 (62) 13 (59) 208 (63) 
Female 70 (44) 30 (30) 3 (12) 10 (38) 9 (41) 122 (37) 
Tumor stage, No. 
(%) 
     
 
I-III 154 (97) 90 (92) 25(96) 25(96) 20 (91) 314 (95) 
IV 4 (3) 8 (8) 1 (4) 1 (4) 2 (9) 16 (5) 
Multiple LS tumors 
b, No. (%) 
     
 
Synchronous 8 (5) 6 (6) 1 (4) 1 (4) 1 (5) 17 (5) 
Metachronous 14 (9) 13 (13) 0 (0) 3 (11) 4 (18) 34 (10) 
No 136 (86) 79 (81) 25 (96) 22 (85) 17 (77) 279 (85) 
Relatives with LS 
tumors c, No. (%) 
     
 
Yes 48 (30) 36 (37) 7 (27) 9 (35) 5 (23) 105 (32) 
No 110 (70) 62 (63) 19 (73) 17 (65) 17 (77) 225 (68) 
aLoss of 3 MMR proteins or unpaired loss 
bLS tumors: Lynch syndrome related tumors, colorectal, endometrial, ovarian, gastric, hepatobiliary, 
small bowel, urinary tract, pancreatic, and brain cancer 
cYes, if any first- or second-degree relative with LS tumors. 
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Table2.Performance of different Strategies for the Identification of Patients with Lynch 
Syndrome
a
 
  
Case (%) 
Diagnostic 
Yield 
Sensitivity Specificity  PPV NPV 
Patie
nts 
requir
ing 
MMR 
testin
g 
Patient
s 
requiri
ng 
germli
ne 
sequen
cing 
Case/T
otal 
No. 
% 
 
(95
% 
CI) 
Case/T
otal 
No. 
% 
 
(95% 
CI) 
Case/T
otal 
No. 
% 
 
(95
% 
CI) 
Case/T
otal 
No. 
% 
 
(95
% 
CI) 
Case/T
otal 
No. 
% 
 
(95
% 
CI) 
Amster
dam 
criteria 
II  
0 (0) 
35 
(1.1) 
9/3191 
0.3  
(0.
1, 
0.5
) 
9/93 
9.7  
(3.7, 
15.7) 
3072/3
098 
99.
2 
 
(98
.9, 
99.
5) 
9/35 
25.
7  
(11
.2, 
40.
2) 
3072/3
156 
97.
3  
(96
.7, 
97.
9) 
revised 
Bethes
da 
guideli
nes 
1046 
(32.7) 
164 
(5.1) 
76/319
1 
2.4  
(1.
9, 
2.9
) 
76/93 
81.7  
(73.8, 
89.6) 
3010/3
098 
68.
7 
 
(67
.1, 
70.
3) 
76/164 
7.3  
(5.
7, 
8.9
) 
3010/3
027 
99.
2  
(98
.8, 
99.
6) 
Univer
sal 
screeni
ng 
3191 
(100) 
256 
(8.0) 
93/319
1 
2.9  
(2.
3, 
3.5
) 
93/93 
100 
(96.1, 
100) 
2935/3
098 
94.
7  
(93
.9, 
95.
4) 
93/256 
36.
3  
(30
.4, 
42.
2) 
2935/2
935 
100 
(99
.9, 
100
) 
Selecti
ve 
strateg
yb 
3191 
(100) 
235 
(7.4) 
93/319
1 
2.9  
(2.
3, 
3.5
) 
93/93 
100(9
6.1, 
100) 
2956/3
098 
95.
4  
(94
.7, 
96.
1) 
93/235 
39.
6  
(33
.3, 
45.
9) 
2956/2
956 
100 
(99
.9, 
100
) 
a The strategies for Lynch Syndrome screening were evaluated in 3191 patients. Those with MMR 
protein deficiency but refuse further germline testing (59 patients) were excluded. 
bSelective strategy：Universal tumor MMR testing as the first line screening, then germline sequencing 
was only performed in patientswith MMRprotein deficiency who were diagnosed at 65 years or 
younger, and in older patients fulfilling at least 1 criterion of the revised Bethesda guidelines 
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Novelty and Impact:  
The prevalence of Lynch syndrome (LS) varies significantly in different ethnic 
populations. In this study, the authors screened more than 3,000 Chinese colorectal 
cancer patients for mutations associated with LS, including mismatch repair (MMR) 
and BRAF
V600E 
mutations. They found that, while the prevalence of LS in Chinese 
patients is similar to that of Western populations, the spectrum of mutations is 
different, including many not previously reported. Older patients had a decreased risk 
of LS, suggesting that germline sequencing may not be necessary in this population. 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
